• About Us
    • Company Overview
    • Leadership
    • Locations
  • Nelmastobart
    • Novel Immune-Checkpoint BTN1A1
    • Main Indications
  • R&D
    • Research Achievements
    • Pipeline
  • IR
    • Public Disclosure Information
    • Stock Price Information
    • IR Materials
  • PR
    • Press Release
    • Notices
  • Careers
    • Careers
  • Partnership
    • Partnership
ENG
  • KOR
  • ENG
  • About Us
    • Company Overview
    • Leadership
    • Locations
  • Nelmastobart
    • Novel Immune-Checkpoint BTN1A1
    • Main Indications
  • R&D
    • Research Achievements
    • Pipeline
  • IR
    • Public Disclosure Information
    • Stock Price Information
    • IR Materials
  • PR
    • Press Release
    • Notices
  • Careers
    • Careers
  • Partnership
    • Partnership
PR
STCube is dedicated to developing precision-driven immunotherapies,
bringing new hope to more cancer patients.
  • Press Release
  • Notices
Press Release
  • Press Release
  • Notices
Press Release
  • Home
  • PR
  • Press Release
  • [데일리팜] 에스티큐브 "BTN1A1, PD-L1 비발현·내성암서 효과 확인"
    2025.10.23
  • 에스티큐브, 비소세포폐암 2상 IND 승인…1b상 없이 본임상 직행
    2025.10.16
  • 에스티큐브, 전이성 대장암에서 'BTN1A1 고발현군 mPFS 6.3개월'…표준치료 성과 넘어
    2025.10.13
  • 에스티큐브, ESMO 2025 참가…BTN1A1 연구성과로 '임상 경쟁력 부각'
    2025.10.01
  • [머니투데이] "글로벌 빅파마가 주목하는 BTN1A1"…에스티큐브 '시장 잠재력' 강조
    2025.09.25
  • [더바이오] "'넬마스토바트', 임상과 기술이전 동시에" 에스티큐브, 바이오마커 '승부수'
    2025.09.25
  • 에스티큐브 "'넬마스토바트+도세탁셀' 병용, 강력한 종양 억제 효과 확인"
    2025.09.16
  • 에스티큐브, 비소세포폐암 임상 2상 IND 접수…"BTN1A1 고발현 암종 타깃"
    2025.08.26
  • 에스티큐브, 비소세포폐암에서 BTN1A1 타깃 치료 효과 확인 "WCLC 발표"
    2025.08.18
1 2 3 4 5

2201, Trade Center Trade Tower, 511 Yeongdong-daero, Gangnam-gu, Seoul, Republic of Korea

Tel : +82-2-551-3370

Copyright by STCube All Rights Reserved.